Vistry Group provides boost to charity as prostate cancer named most commonly diagnosed cancer in the UK

16 June 2020

Tracey Pritchard, director of Fundraising and Engagement at Prostate Cancer UK
Tracey Pritchard, director of Fundraising and Engagement at Prostate Cancer UK 
Vistry Group – which includes Bovis Homes and Linden Homes – has donated £5,000 to Prostate Cancer UK, as prostate cancer becomes the most commonly diagnosed cancer in the UK for the first time.

Covid-19 has interrupted crucial research conducted by the charity, which is why donations are essential at this time, to ensure important work continues and more lives are saved.

Tracey Pritchard, director of Fundraising and Engagement at Prostate Cancer UK, said: “I would like to thank everyone at Vistry Group for their donation to Prostate Cancer UK. Prostate cancer is now the most commonly diagnosed form of cancer in the UK, and over 400,000 men and their families are living with the disease.

“The Covid-19 pandemic hasn’t just disrupted healthcare – it’s disrupted vital research too. While our research came to a standstill, prostate cancer didn’t. Vistry’s generous donation will go towards lifesaving research into treatments and better tests to stop the disease being a killer; as well as to men and their families accessing our support service during these challenging times.”

Thank you from Prostate Cancer UKChris Jones, head of Internal Audit and Risk at Vistry, added: “Due to the impact of the coronavirus pandemic, cancer patients are really suffering through a lack of mobility and the withdrawal of some community and NHS services. As such, charities like Prostate Cancer UK are stretched at the same time as their donations drop. Which is why we are so pleased to make this contribution to ensure the charity can continue its vital work”.

Latest figures for cancer diagnoses in England, Scotland, Northern Ireland and Wales, when combined, bring the total number of prostate cancer diagnoses in the UK to 57,192, exceeding those of breast, lung and bowel cancers.

Prostate Cancer UK's top priority is funding research to stop prostate cancer killing men. The charity is investing millions to find better treatments and better tests that can spot fast-growing cancers early, and could be used in a screening programme to save thousands of lives.

You can support Prostate Cancer UK at this challenging time by visiting 

For more information about Vistry Group, visit

About Prostate Cancer UK
o Prostate Cancer UK has a simple ambition – to stop men dying from prostate cancer. We’re investing millions to find better treatments and tests that could save thousands of lives.
o We work with the NHS to make sure men get access to breakthrough tests and treatments.
o We spread the word about who is at risk of prostate cancer, especially to those at higher risk.
o We support people dealing with prostate cancer and provide health information.
o Visit now to help beat this disease.

About Covid-19 and prostate cancer
o Covid-19 brought prostate cancer research to a standstill. 
o Prostate Cancer UK is calling for support to raise the millions of pounds needed to ensure the charity’s ground-breaking research is able to continue.
o Prostate cancer does not stop for Covid-19. Around 400,000 men in the UK are living with or after prostate cancer, it’s the most common cancer in men.
o This highlights the importance of more research to develop the tests and treatments needed to ensure that as many of these men as possible have their prostate cancer caught early and successfully treated.
o To donate to Prostate Cancer UK, visit